IGC Pharma, Inc.
IGC
AMEX·Healthcare·Biotechnology·Mkt cap $29.8M
$0.30
▼ -0.17%
P/E
-3.99
Mkt Cap
$29.8M
52-Wk Range
$0.24–$0.45
52-Week Range
$0.24 - $0.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 28.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.5).
Growth
Mild headwinds expected
Value
Deep value opportunity - significant discount to sector peers
Momentum
Stable
-0.3% over 3m
Quality
Stable
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying IGC right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 13, 2026
AUG 14, 2026
Reported EPS of -$0.03 vs -$0.02 consensus (-50.0% surprise). Revenue of $265.0K vs $164.0K expected (+61.6%).
EPS surprise · last 4Q
1 of 2 beats
Estimate
Actual
Q3 26
-50.0%
Q2 26
0.0%
Revenue trend · last 3Q
—
-4%
-19%
Q1 26
Q4 26
Q1 27
$328.0K
$317.0K
$265.0K
Margins · last 3Q
Gross
18.1%
Profit
-1107.9%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Ascendiant Capital · Apr 8, 2026
vs Industry
How IGC stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.